1. Search Result
Search Result
Results for "

CD28

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

2

Peptides

18

Inhibitory Antibodies

3

Natural
Products

37

Recombinant Proteins

4

Antibodies

1

Click Chemistry

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99123

    CD28 Inflammation/Immunology
    Anti-Mouse CD28 Antibody is an anti-mouse CD28 IgG antibody inhibitor derived from the host Syrian Hamster.
    Anti-Mouse CD28 Antibody (37.51)
  • HY-P99302

    Humanized Anti-CD28 Recombinant Antibody

    CD28 Inflammation/Immunology
    Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is a selective CD28 blockade, Lulizumab prevents T cell activation by selectively targeting CD28 signaling .
    Lulizumab
  • HY-102090

    CD28 Inflammation/Immunology
    B7/CD28 interaction inhibitor 1 (copmound 6b) is a potent B7.1-CD28 interaction inhibitor with an IC50 of 50 nM .
    B7/CD28 interaction inhibitor 1
  • HY-100891

    CD28 Inflammation/Immunology
    CD80-IN-3, a potent CD80 inhibitor, inhibits CD80/CD28 interaction with an EC50 of 630 nM and a Kd of 125 nM.
    CD80-IN-3
  • HY-P99420

    ALPN-101

    CD28 Inflammation/Immunology
    Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities .
    Acazicolcept
  • HY-P1698

    AB-103

    Bacterial CD28 Infection Inflammation/Immunology
    Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs) .
    Reltecimod
  • HY-P1698B

    AB-103 TFA

    Bacterial CD28 Infection Inflammation/Immunology
    Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs) .
    Reltecimod TFA
  • HY-RS02221

    Small Interfering RNA (siRNA) Others

    CD28 Human Pre-designed siRNA Set A contains three designed siRNAs for CD28 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CD28 Human Pre-designed siRNA Set A
    CD28 Human Pre-designed siRNA Set A
  • HY-RS02222

    Small Interfering RNA (siRNA) Others

    Cd28 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cd28 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cd28 Mouse Pre-designed siRNA Set A
    Cd28 Mouse Pre-designed siRNA Set A
  • HY-RS02223

    Small Interfering RNA (siRNA) Others

    Cd28 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cd28 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cd28 Rat Pre-designed siRNA Set A
    Cd28 Rat Pre-designed siRNA Set A
  • HY-P9975

    TGN1412

    CD28 Inflammation/Immunology
    Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis .
    Theralizumab
  • HY-P990752

    REGN-5678

    CD28 Inflammation/Immunology
    Nezastomig is an anti-FOLH1/CD28 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Nezastomig
  • HY-N10445

    CD28 CD3 Inflammation/Immunology
    Maydispenoid A is a potent immunosuppressor. Maydispenoid A can inhibit anti-CD3/anti-CD28 mAbs activated and lipopolysaccharide activated murine splenocyte proliferation .
    Maydispenoid A
  • HY-N10446

    CD28 CD3 Inflammation/Immunology
    Maydispenoid B is a potent immunosuppressor. Maydispenoid B can inhibit anti-CD3/anti-CD28 mAbs activated and lipopolysaccharide activated murine splenocyte proliferation .
    Maydispenoid B
  • HY-P99157

    CD276/B7-H3 Cancer
    Omburtamab is an anti-CD276 (also known as B7-H3) monoclonal antibody, CD276 is a B7/CD28 immunoglobulin superfamily member expressed among solid human tumours. Omburtamab can bind tumor tissues and be used in various cancers research .
    Omburtamab
  • HY-P99293

    IDEC 114; Anti-Human CD80 Recombinant Antibody

    CD28 Cancer
    Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen and blocks CD80–CD28 binding. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma .
    Galiximab
  • HY-156520

    Apoptosis Inflammation/Immunology
    Immunosuppressant-1 (Compound 31) inhibits anti-CD3/anti-CD28 co-stimulated T-cell proliferation. Immunosuppressant-1 has immunosuppressive activity, and induces apoptosis by activating caspase-3 and PARP in activated lymph node cells .
    Immunosuppressant-1
  • HY-159123

    MAP4K Cancer
    KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC50 of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ T cells, and enhances T cell-mediated killing activity of SKOV3 and A549 cells .
    KHK-6
  • HY-19486

    Nuclear Factor of activated T Cells (NFAT) CD3 CD28 Interleukin Related Inflammation/Immunology
    UR-1505 is a nuclear factor of activated T cells (NF-AT) inhibitor. UR-1505 can suppress CD3/CD28 induced T cell proliferation, increase p27 KIP levels, and induce G1/S cell cycle arrest. UR-1505 can also inhibit the production of IL-5 and IFN-γ in activated T cells. UR-1505 has immunomodulatory properties and can be used in the study of atopic dermatitis .
    UR-1505
  • HY-120622

    Src Cancer
    BMS-243117 is a potent, and selective benzothiazole based p56 Lck inhibitor with an IC50 of 4 nM. BMS-243117 inhibits anti-CD3/anti-CD28 induced PBL (human peripheral blood T-cells) proliferation with an IC50 of 1.1 μM. BMS-243117 binds in an extended conformation to the ATP-binding site of Lck .
    BMS-243117
  • HY-113545

    9(R)-Hydroxyoctadecadienoic acid

    Endogenous Metabolite Metabolic Disease
    9(R)-HODE is a monohydroxy fatty acid and metabolite of linoleic acid. It is formed from linoleic acid by COX and lipoxygenase (LO).9(R)-HODE induces chemotaxis, increases the levels of chemokine (C-C motif) receptor 9 (CCR9) and chemokine (C-X-C motif) receptor 4 (CXCR4), and inhibits IL-6 release in primary human monocytes. It inhibits CD3α- and CD28-induced proliferation of isolated human peripheral blood lymphocytes when used at a concentration of 25 μg/mL.
    9(R)-HODE
  • HY-108813

    BMS 224818; LEA 29Y

    Others Inflammation/Immunology
    Belatacept (BMS 224818) is a selective T-cell costimulation blocker. Belatacept binds to CD 80/86 ligands and thereby inhibits the CD-28-mediated T-cell costimulation. Belatacept can be used in the research of Immunosuppression in organ transplants .
    Belatacept
  • HY-108829
    Abatacept
    1 Publications Verification

    CTLA4lg; BMS-188667

    CTLA-4 Inflammation/Immunology Cancer
    Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
    Abatacept
  • HY-108829A
    Abatacept (powder)
    1 Publications Verification

    CTLA4lg (powder); BMS-188667 (powder)

    CTLA-4 Inflammation/Immunology Cancer
    Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
    Abatacept (powder)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: